NAPOLI 3: UGT1A1*28 Polymorphism and Tolerability in Patients With mPDAC Treated With NALIRIFOX
By Maen Abdelrahim, MD, PhD - Last Updated: March 19, 2025At the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Maen Abdelrahim, MD, PhD, of Houston Methodist Neal Cancer Center, details the impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 study.
Advertisement
He also explains how testing for UGT1A1*28 polymorphism may improve personalized treatment strategies for patients with mPDAC receiving NALIRIFOX.
Advertisement
Related Posts
Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.
Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.
Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.
Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.
Drs. Stephen Liu and Benjamin Weinberg elaborate on the prevalence of NRG1 gene fusions in PDAC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.